Plan quality assessment in clinical practice: Results of the 2020 ESTRO survey on plan complexity and robustness.


Journal

Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology
ISSN: 1879-0887
Titre abrégé: Radiother Oncol
Pays: Ireland
ID NLM: 8407192

Informations de publication

Date de publication:
08 2022
Historique:
received: 17 02 2022
revised: 24 05 2022
accepted: 07 06 2022
pubmed: 18 6 2022
medline: 4 8 2022
entrez: 17 6 2022
Statut: ppublish

Résumé

Plan complexity and robustness are two essential aspects of treatment plan quality but there is a great variability in their management in clinical practice. This study reports the results of the 2020 ESTRO survey on plan complexity and robustness to identify needs and guide future discussions and consensus. A survey was distributed online to ESTRO members. Plan complexity was defined as the modulation of machine parameters and increased uncertainty in dose calculation and delivery. Robustness was defined as a dose distribution's sensitivity towards errors stemming from treatment uncertainties, patient setup, or anatomical changes. A total of 126 radiotherapy centres from 33 countries participated, 95 of them (75%) from Europe and Central Asia. The majority controlled and evaluated plan complexity using monitor units (56 centres) and aperture shapes (38 centres). To control robustness, 98 (97% of question responses) photon and 5 (50%) proton centres used PTV margins for plan optimization while 75 (94%) and 5 (50%), respectively, used margins for plan evaluation. Seventeen (21%) photon and 8 (80%) proton centres used robust optimisation, while 10 (13%) and 8 (80%), respectively, used robust evaluation. Primary uncertainties considered were patient setup (photons and protons) and range calculation uncertainties (protons). Participants expressed the need for improved commercial tools to control and evaluate plan complexity and robustness. Clinical implementation of methods to control and evaluate plan complexity and robustness is very heterogeneous. Better tools are needed to manage complexity and robustness in treatment planning systems. International guidelines may promote harmonization.

Identifiants

pubmed: 35714808
pii: S0167-8140(22)04150-0
doi: 10.1016/j.radonc.2022.06.005
pii:
doi:

Substances chimiques

Protons 0

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

254-261

Informations de copyright

Copyright © 2022 The Authors. Published by Elsevier B.V. All rights reserved.

Déclaration de conflit d'intérêts

Declaration of Competing Interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.

Auteurs

Laura Patricia Kaplan (LP)

Department of Oncology, Aarhus University Hospital, Denmark; Department of Clinical Medicine, Aarhus University, Denmark. Electronic address: lakap@regionsjaelland.dk.

Lorenzo Placidi (L)

Fondazione Policlinico Universitario ''A. Gemelli'' IRCCS, Roma, Italy. Electronic address: lorenzo.placidi@policlinicogemelli.it.

Anna Bäck (A)

Department of Therapeutic Radiation Physics, Sahlgrenska University Hospital, Gothenburg, Sweden; Department of Medical Radiation Sciences, Sahlgrenska Academy, University of Gothenburg, Sweden.

Richard Canters (R)

Department of Radiation Oncology (Maastro), GROW School for Oncology, Maastricht University Medical Centre+, the Netherlands.

Mohammad Hussein (M)

Metrology for Med Phys Centre, National Physical Laboratory, Teddington, United Kingdom.

Ana Vaniqui (A)

Department of Radiation Oncology (Maastro), GROW School for Oncology, Maastricht University Medical Centre+, the Netherlands.

Marco Fusella (M)

Department of Med Phys, Veneto Institute of Oncology - IOV IRCCS, Padua, Italy.

Tomasz Piotrowski (T)

Department of Electroradiology, Poznan University of Medical Sciences and Department of Med Phys, Greater Poland Cancer Centre, Poznan, Poland.

Victor Hernandez (V)

Department of Med Phys, Hospital Sant Joan de Reus, IISPV, Spain.

Nuria Jornet (N)

Servei de Radiofísica i Radioprotecció, Hospital de la Santa Creu i Sant Pau, Barcelona, Spain.

Christian Rønn Hansen (CR)

Laboratory of Radiation Physics, Department of Oncology, Odense University Hospital, Denmark; Danish Centre for Particle Therapy, Aarhus University Hospital, Denmark; Department of Clinical Research, University of Southern Denmark, Odense, Denmark.

Lamberto Widesott (L)

Centro di protonterapia, APSS, Trento, Italy.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH